|

TAR-210 Clinical Trials

1 actively recruiting trial across 1 location

No change since June 2026

Also known as: JNJ-42756493

Pipeline

Phase 3: 1

Top Sponsors

  • Janssen Research & Development, LLC1

Indications

  • Non-Muscle Invasive Bladder Neoplasms1
  • Cancer1

Sun City, Arizona1 trial

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Academic Urology and Urogynecology of Arizona

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.